As The Beacon previously reported, Spanish researchers recently presented clinical trial results showing that active treatment may be beneficial for some smoldering multiple myeloma patients.

Specifically, the results of the study showed that high-risk smoldering multiple myeloma patients who received Revlimid plus dexametha­sone followed by Revlimid maintenance had a longer time to disease progression and better overall survival than patients who did not receive treatment (see related Beacon news).

To help Beacon readers put these results into perspective and better understand their implications, The Beacon asked myeloma specialist Dr. Ola Landgren for …

Dr. Kenneth Anderson, a world-renowned myeloma spe­cialist, physician and re­searcher at Dana-Farber Cancer In­sti­tute, and Kraft Family Pro­fessor at Harvard Medical School, spoke with The Myeloma Beacon about his ap­proach to treating mul­ti­ple myeloma patients.

This article is the sec­ond part of a two-part series based on The Myeloma Beacon’s interview with Dr. Anderson.  It will cover Dr. Anderson’s thoughts on where myeloma treat­ment is headed in the com­ing years.  For more in­­for­ma­tion on Dr. Anderson’s cur­rent ap­proach to treating mul­ti­ple myeloma, please see part one of this series.

Emerging Therapies …

Dr. Kenneth Anderson is a multiple myeloma thought leader, physician and researcher at Dana-Farber Cancer Institute, where he is Director of the Jerome Lipper Multiple Myeloma Center.  He also is the Kraft Family Professor of Medicine at Harvard Medical School in Boston.

Dr. Anderson's research has played a key role in the development of several new multiple myeloma drugs and, more broadly, the significant improvement in treatment outcomes for myeloma patients that has occurred over the past 10 to 15 years.

In an interview with The Myeloma Beacon, Dr. Anderson spoke about his approach to treating …

Dr. Robert Kyle, a leading myeloma physician, researcher, and professor at the Mayo Clinic, spoke with The Myeloma Beacon about his approach to treating multiple myeloma patients; participation in clinical trials; many of the key issues for myeloma patients and physicians, including conventional and alternative treatment options; and the future of personalized medicine.

This article is the second part of a two-part series based on the Beacon’s conversations with Dr. Kyle. It will cover the role of clinical trials and key issues in the treatment of multiple myeloma as well as promising …

Dr. Robert Kyle is a multiple myeloma key opinion leader, physician, researcher, and professor at the Mayo Clinic. Dr. Kyle has dedicated his life to caring for multiple myeloma patients and studying the disease.

His work in myeloma began with his residency at the Mayo Clinic in the late 1950s, where he measured monoclonal protein levels in more than 6,500 myeloma and non-myeloma patients to identify a spike characteristic of multiple myeloma. He has authored more than 850 research papers and won lifetime achievement awards from the International Myeloma Foundation and the …